MYLIP and Hypercholesterolemia: Since its discovery in 2009,11 mounting genetic evidence suggests that IDOL is a viable pharmacological target for the treatment of hypercholesterolemia.19 However, no compounds have been reported to date that are capable of inhibiting IDOL mediated LDLR degradation.